摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2.3-二氟-6-甲氧基苯硼酸 | 957061-21-1

中文名称
2.3-二氟-6-甲氧基苯硼酸
中文别名
2,3-二氟-6-甲氧基苯硼酸;2,3-丁二酮一肟
英文名称
2,3-Difluoro-6-methoxyphenylboronic acid
英文别名
(2,3-difluoro-6-methoxyphenyl)boronic acid
2.3-二氟-6-甲氧基苯硼酸化学式
CAS
957061-21-1
化学式
C7H7BF2O3
mdl
MFCD03095116
分子量
187.94
InChiKey
IWTBPDRQHIEPBQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    322.4±52.0 °C(Predicted)
  • 密度:
    1.35±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.67
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.142
  • 拓扑面积:
    49.7
  • 氢给体数:
    2
  • 氢受体数:
    5

安全信息

  • 危险等级:
    IRRITANT
  • 海关编码:
    2931900090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

制备方法与用途

2,3-二氟-6-甲氧基苯硼酸是一种安全环保的新型芳基化试剂,广泛应用于医药、农药及先进材料等领域中含芳基结构的精细化学品的科研与生产。

反应信息

  • 作为反应物:
    描述:
    tert-butyl N-[2-bromo-4-[[5-[(2S,5R,6R)-5-(tert-butoxycarbonylamino)-6-fluoro-oxepan-2-yl]-1-methyl-pyrazol-4-yl]carbamoyl]thiazol-5-yl]carbamate 、 2.3-二氟-6-甲氧基苯硼酸 以gave 277的产率得到5-amino-N-(5-((2S,5R,6R)-5-amino-6-fluorooxepan-2-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2,3-difluoro-6-methoxyphenyl)thiazole-4-carboxamide
    参考文献:
    名称:
    Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
    摘要:
    公式I中的环氧杂环基羧酰胺化合物,包括立体异构体、几何异构体、互变异构体和其药学上可接受的盐,其中R2是一个环氧杂环基,X是噻唑基、吡嗪基、吡啶基或嘧啶基,用于抑制Pim激酶,并用于治疗由Pim激酶介导的癌症等疾病。本文介绍了利用公式I中的化合物在哺乳动物细胞中进行体外、原位和体内诊断、预防或治疗此类疾病或相关病理条件的方法。
    公开号:
    US09328106B2
点击查看最新优质反应信息

文献信息

  • IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES
    申请人:Howard Steven
    公开号:US20120101064A1
    公开(公告)日:2012-04-26
    The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N + —O − or CR 3 ; Y is N, N + —O − or CR 3a ; R 1 and R 2 are independently selected from hydrogen and various substituents as defined in the claims; or R 1 and R 2 together with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; R 3 is selected from hydrogen and various substituents; and R 3a is selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers.
    本发明提供了式(I)的化合物及其盐,互变异构体,溶剂合物和N-氧化物;其中Q为CH或N;X为N,N+—O−或CR3;Y为N,N+—O−或CR3a;R1和R2分别选自氢和定义在权利要求中的各种取代基;或者R1和R2与它们附着的原子一起连接形成一个可选取代的4到7个成员的碳环芳香族或杂环芳香族或非芳香族环;R3选自氢和各种取代基;而R3a选自氢和定义在权利要求中的各种取代基。还提供了含有式(I)化合物的药物组合物,制备化合物的过程以及化合物的医药用途。式(I)化合物具有作为CDK激酶抑制剂的活性,并可用于治疗增殖性疾病,如癌症等。
  • CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE
    申请人:Genentech, Inc.
    公开号:US20140088117A1
    公开(公告)日:2014-03-27
    Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R 2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    公式I中的环氧杂环基卡氧酰胺化合物,包括立体异构体、几何异构体、互变异构体和其药学上可接受的盐,其中R2是环氧杂环基,X是噻唑基、吡嗪基、吡啶基或嘧啶基,可用于抑制Pim激酶,并用于治疗由Pim激酶介导的癌症等疾病。公开了使用公式I中的化合物进行哺乳动物细胞中的体外、体内和原位诊断、预防或治疗此类疾病或相关病理条件的方法。
  • Imidazole derivatives and their use as modulators of cyclin dependent kinases
    申请人:Howard Steven
    公开号:US08598217B2
    公开(公告)日:2013-12-03
    The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N+—O− or CR3; Y is N, N+—O− or CR3a; R1 and R2 are independently selected from hydrogen and various substituents as defined in the claims; or R1 and R2 together with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; R3 is selected from hydrogen and various substituents; and R3a is selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers.
    本发明提供了公式(I)的化合物及其盐、互变异构体、溶剂合物和N-氧化物;其中Q为CH或N;X为N、N+—O−或CR3;Y为N、N+—O−或CR3a;R1和R2独立地选择氢和各种取代基,如权利要求中所定义的;或者R1和R2与它们所连接的原子一起,链接形成一个选择性取代的4到7个成员的碳环或杂环芳香或非芳香环;R3选择氢和各种取代基;R3a选择氢和各种取代基,如权利要求中所定义的。还提供了含有公式(I)化合物的制药组合物、制备化合物的方法以及化合物的医药用途。公式(I)化合物具有作为CDK激酶抑制剂的活性,并且在治疗增殖性疾病,如癌症等方面是有用的。
  • Thiazole derivatives
    申请人:Banno Hiroshi
    公开号:US09090601B2
    公开(公告)日:2015-07-28
    The present invention relates to a compound represented by the formula (I) or (I′): wherein each symbol is as defined in the specification, or a salt thereof, and a PI3K and(or) mTOR inhibitor containing the compound or a prodrug thereof.
    本发明涉及一种由式(I)或(I′)表示的化合物:其中每个符号如规范中所定义,或其盐,以及含有该化合物或其前药的PI3K和(或)mTOR抑制剂。
  • Heteroaryls and uses thereof
    申请人:Hirose Masaaki
    公开号:US09139589B2
    公开(公告)日:2015-09-22
    This invention provides compounds of formula IA or IB: wherein R1, R2, G1 and HY are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    本发明提供了公式IA或IB的化合物:其中R1,R2,G1和HY如说明书中所述。这些化合物是PI3K和/或mTor的抑制剂,因此可用于治疗增殖性,炎症性或心血管疾病。
查看更多